Four
new oxidovanadium [VVOL1–4(ema)]
complexes (1–4) have been synthesized
using tridentate binegative ONO donor ligands H2L1–4 [H2L1: (E)-N′-(2-hydroxybenzylidene)furan-2-carbohydrazide; H2L2: (E)-N′-(4-(diethylamino)-2-hydroxybenzylidene)thiophene-2-carbohydrazide;
H2L3: (E)-2-(4-(diethylamino)-2-hydroxybenzylideneamino)-4-methylphenol;
H2L4: (E)-2-(3-ethoxy-2-hydroxybenzylideneamino)-4-methylphenol]
and ethyl maltol (Hema) as a bidentate uninegative coligand and characterized
by CHNS analysis, IR, UV–vis, NMR, and HR–ESI–MS
methods. The structures of 1, 3, and 4 are confirmed by single-crystal X-ray analysis. The hydrophobicity
and hydrolytic stability of the complexes are tested using NMR and
HR–ESI–MS and correlated with their observed biological
activities. It is observed that 1 hydrolyzed into a penta-coordinated
vanadium-hydroxyl species (VVOL1-OH) with the
release of ethyl maltol, whereas 2–4 are found quite stable under the investigated time period. The biomolecular
interaction of 1–4 with DNA and BSA
was performed using absorbance, fluorescence, and circular dichroism
techniques. The in vitro cytotoxicity activities
of H2L1–4 and 1–4 were tested against A549, HT-29, and NIH-3T3 cell lines.
Among complexes, 2 with an IC50 value of 4.4
± 0.1 μM displayed maximum anticancer activity against
the HT-29 cell line. Complexes induce cell cycle arrest at the G2/M
phase and subsequently trigger dose-dependent cell apoptosis, which
is obtained by the cell apoptosis analysis via flow cytometry and
confocal microscopy assays. Being fluorescence active, 1–4 were observed to target the mitochondria and
exhibit disruption of the mitochondrial membrane potential, which
consequently causes overproduction of intracellular reactive oxygen
species and induced cell apoptosis.